Physician profile
Faaiza Arshad
NPI 1144887001
$3,261.15
in general payments reported to CMS, 2019-2025
35 companies · $730 in 2025
The $730 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $673 · 2022: $711 · 2023: $695 · 2024: $452 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $461.11 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $363.18 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Novo Nordisk INC | $287.48 | 2021-2023 | Ozempic, Rybelsus |
| Amgen INC. | $282.90 | 2022-2025 | Otezla, Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $240.66 | 2021-2022 | |
| Abbvie INC. | $204.94 | 2021-2024 | |
| Lundbeck LLC | $187.57 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $163.24 | 2023-2025 | Gemtesa, Aptiom |
| Merck Sharp & Dohme LLC | $125.66 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $118.79 | 2021-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $113.88 | 2021-2023 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $81.27 | 2024-2025 | Cobenfy |
| Indivior INC. | $63.72 | 2022-2024 | Perseris |
| Pfizer INC. | $53.79 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.27 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $42.13 | 2022-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $41.01 | 2021 | |
| Grifols USA, LLC | $37.72 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.95 | 2022-2023 | Gattex |
| Astellas Pharma US INC | $34.72 | 2021-2023 | Myrbetriq |
| Neurocrine Biosciences, INC. | $30.96 | 2022 | |
| Amneal Pharmaceuticals LLC | $29.55 | 2022-2023 | Lyvispah |
| Biogen, INC. | $23.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.88 | 2024 | |
| Abbott Laboratories | $18.66 | 2022 | |
| Vanda Pharmaceuticals INC. | $17.50 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.70 | 2025 | Uzedy |
| Paratek Pharmaceuticals, INC. | $16.37 | 2023 | Nuzyra |
| Janssen Pharmaceuticals, INC | $15.87 | 2021 | |
| Glaxosmithkline, LLC. | $15.72 | 2025 | Trelegy Ellipta |
| Impel Pharmaceuticals INC. | $14.50 | 2022 | |
| Averitas Pharma INC. | $14.34 | 2025 | Qutenza |
| Supernus Pharmaceuticals, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faaiza Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.